Clinical Trials Browser

Observational × venetoclax × Clear all

NCT04589728 2025-07-08

Prospective and Retrospective Observational Evaluation of Real World Outcome of Unfit AML Patients Treated With the Combination Venetoclax Plus Hypomethylating Agents, Under the Italian Law No.648/96

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT06390306 2025-06-03

The Efficacy and Safety of Third-generation TKIs Combined With Azacitidine and Bcl-2 Inhibitor in Patients With CML-MBP

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT06993883 2025-05-29

AML

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT04282811 2025-01-17

Observational Study Relapsed or Refractory Chronic Lymphocytic Leukemia Venetoclax-based Regimens Outside Clinical Trials in Italy

LymphoidOther hematologic neoplasm

Leukemia, Leukemia, Lymphocytic, Chronic, B-Cell

NCT03873857 2023-09-01

FORTE

LymphoidOther hematologic neoplasm

Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell

NCT04230564 2023-06-07

Acute Myeloid Leukemia Real World Treatment Patterns

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT05312112 2023-03-02

Real World Outcomes Using Novel Agents for AML in the UK

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT04613622 2021-10-28

Pharmacokinetics of Venetoclax in Patients With Acute Myeloid Leukemia

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT04616274 2021-10-28

Pharmacokinetics of Venetoclax in Patients With Chronic Lymphocytic Leukemia

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03662724 2021-02-16

VENreg

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT04454580 2020-09-16

Hypomethylating Agents and Venetoclax in Newly Diagnosed Acute Myeloid Leukemia Patients Not Eligible for Intensive Chemotherapy

Other hematologic neoplasm

Leukemia, Myeloid, Acute